Endress+Hauser Completes Takeover of Analytik Jena
Remaining minority shareholders receive cash compensation
Swiss measurement and automation engineering specialist Endress+Hauser has completed the takeover of analytical instrumentation provider Analytik Jena. The remaining minority shares of Analytik Jena were legally transferred to Endress+Hauser on 30 March 2016 following the entry of the transfer resolution in the commercial registry that was previously adopted at the extraordinary general meeting in February. The process will now be finalized with the agreed-upon cash payout to the minority shareholders.
In the run up to the completed takeover, as majority shareholder Endress+Hauser owned all but 3.4 percent of the Analytik Jena shares. The demand for the remaining shares was delivered to Analytik Jena in September 2015. This set the final part of the takeover process in motion, during which an independent appraiser fixed the value of the company at 13.68 euros per share.
Endress+Hauser gained control of publicly-traded Analytik Jena AG in 2013, most recently holding 96.6 percent of the shares. The goal of the acquisition is to eventually be at the side of both companies’ customers from the lab to the process, giving support from product development to production. Analytik Jena employs nearly 1,000 staff worldwide in its core businesses Analytical Instrumentation and Life Science.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Carl_Freiherr_von_Rokitansky
Actelion announces change in its management structure - Otto Schwarz appointed Chief Operating Officer
EPO for the Brain - Engineered Moss produces human hormone without doping activity
ProtAffin AG granted patent in EU for CellJammer discovery technology - Novel technology enables development of a new class of biopharmaceuticals

CSIC researchers find the role of a protein in the regulation of synapse formation - The work raises the need for a balance between the Pinkman protein and the sHSPs proteins during the development of the nervous system for its correct formation
Affymetrix Selected to Genotype More Than 9,000 Framingham Heart Study Samples - SHARE Project to Help Identify Genetic Variants Associated With Heart, Lung, Blood and Sleep Disorders

New app calculates corona infection risk in rooms - Size of aerosol droplets that virus carriers release strongly influences infectivity
Northern_Norway_Pharmaceutical_Trust
